Market Cap
US$2.4b
Last Updated
2020/04/10 07:14 UTC
Data Sources
Company Financials +
Executive Summary
Amarin Corporation plc, a pharmaceutical company, develops and commercializes therapeutics for the treatment of cardiovascular diseases in the United States.
Rewards
Risk Analysis
Snowflake Analysis
Excellent balance sheet with high growth potential.
Similar Companies
Share Price & News
How has Amarin's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: AMRN's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
26.7%
AMRN
4.0%
US Biotechs
9.4%
US Market
1 Year Return
-68.1%
AMRN
6.1%
US Biotechs
-6.8%
US Market
Return vs Industry: AMRN underperformed the US Biotechs industry which returned 4.6% over the past year.
Return vs Market: AMRN underperformed the US Market which returned -10% over the past year.
Shareholder returns
| AMRN | Industry | Market | |
|---|---|---|---|
| 7 Day | 26.7% | 4.0% | 9.4% |
| 30 Day | -51.8% | 2.2% | -3.9% |
| 90 Day | -68.1% | -1.5% | -16.5% |
| 1 Year | -68.1%-68.1% | 6.9%6.1% | -4.8%-6.8% |
| 3 Year | 94.5%94.5% | 19.2%16.2% | 23.4%15.2% |
| 5 Year | 159.7%159.7% | -5.8%-10.1% | 41.3%25.7% |
Price Volatility Vs. Market
How volatile is Amarin's share price compared to the market and industry in the last 5 years?
Simply Wall St News
4 days ago | Simply Wall St
Amarin (NASDAQ:AMRN) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway3 weeks ago | Simply Wall St
How Does Investing In Amarin Corporation plc (NASDAQ:AMRN) Impact The Volatility Of Your Portfolio?1 month ago | Simply Wall St
Do Institutions Own Amarin Corporation plc (NASDAQ:AMRN) Shares?Valuation
Is Amarin undervalued compared to its fair value and its price relative to the market?
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: AMRN ($5.04) is trading below our estimate of fair value ($53.53)
Significantly Below Fair Value: AMRN is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: AMRN is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: AMRN is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate AMRN's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: AMRN is overvalued based on its PB Ratio (3.1x) compared to the US Biotechs industry average (2.6x).
Next Steps
Future Growth
How is Amarin forecast to perform in the next 1 to 3 years based on estimates from 11 analysts?
50.1%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: AMRN is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.7%).
Earnings vs Market: AMRN is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: AMRN's is expected to become profitable in the next 3 years.
Revenue vs Market: AMRN's revenue (25% per year) is forecast to grow faster than the US market (7% per year).
High Growth Revenue: AMRN's revenue (25% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: AMRN's Return on Equity is forecast to be low in 3 years time (4%).
Next Steps
Past Performance
How has Amarin performed over the past 5 years?
8.4%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: AMRN is currently unprofitable.
Growing Profit Margin: AMRN is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: AMRN is unprofitable, but has reduced losses over the past 5 years at a rate of 8.4% per year.
Accelerating Growth: Unable to compare AMRN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AMRN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (22%).
Return on Equity
High ROE: AMRN has a negative Return on Equity (-3.72%), as it is currently unprofitable.
Next Steps
Financial Health
How is Amarin's financial position?
Financial Position Analysis
Short Term Liabilities: AMRN's short term assets ($855.0M) exceed its short term liabilities ($242.2M).
Long Term Liabilities: AMRN's short term assets ($855.0M) exceed its long term liabilities ($31.7M).
Debt to Equity History and Analysis
Debt Level: AMRN's debt to equity ratio (8.2%) is considered satisfactory.
Reducing Debt: AMRN had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: AMRN has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if AMRN has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Next Steps
Dividend
What is Amarin's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate AMRN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate AMRN's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if AMRN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if AMRN's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of AMRN's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
4.3yrs
Average management tenure
CEO
John Thero (58yo)
6.25s
Tenure
US$4,205,779
Compensation
Mr. John F. Thero has been the Chief Executive Officer of Amarin Corporation Plc since January 1, 2014 and has been its President since November 2010. Mr. Thero serves as the President of U.S. at Amarin Co ...
CEO Compensation Analysis
Compensation vs Market: John's total compensation ($USD4.21M) is about average for companies of similar size in the US market ($USD4.67M).
Compensation vs Earnings: John's compensation has increased whilst the company is unprofitable.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 6.25yrs | US$4.21m | 0.64% $15.1m | |
| CFO, Senior VP & Assistant Secretary | 3.83yrs | US$1.27m | 0.027% $647.7k | |
| President of Research & Development | 4.25yrs | US$1.33m | 0.25% $5.9m | |
| Executive VP | 8.33yrs | US$1.36m | 0.051% $1.2m | |
| Senior Director of Investor Relations | no data | no data | no data | |
| Senior VP & Chief Pharmaceutical Compliance Officer | 1.5yrs | no data | no data | |
| Vice President of Corporate Communications | 0.92yr | no data | no data | |
| Senior Vice President of Corporate Development | 4.25yrs | no data | no data | |
| Senior Vice President of Human Resources | 6.67yrs | no data | no data | |
| Head of Research and Development Operations | 12.33yrs | no data | no data |
4.3yrs
Average Tenure
52.5yo
Average Age
Experienced Management: AMRN's management team is considered experienced (4.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 6.25yrs | US$4.21m | 0.64% $15.1m | |
| Chairman of Scientific Advisory Board | 13.92yrs | US$39.00k | no data | |
| Independent Non-Executive Director | 10.17yrs | US$282.50k | 0.0073% $171.4k | |
| Non-Executive Independent Director | 7.33yrs | US$270.00k | no data | |
| Chairman & Lead Independent Director | 6.25yrs | US$320.01k | no data | |
| Member of Scientific Advisory Board | 13.92yrs | no data | no data | |
| Non-Executive Director | 10.25yrs | US$260.00k | 0.043% $1.0m | |
| Member of the Scientific Advisory Board | 13.92yrs | no data | no data | |
| Member of the Scientific Advisory Board | 13.92yrs | no data | no data | |
| Non-Executive Director | 8.33yrs | US$275.00k | no data |
10.2yrs
Average Tenure
69yo
Average Age
Experienced Board: AMRN's board of directors are seasoned and experienced ( 10.2 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 15.2%.
Top Shareholders
Company Information
Amarin Corporation plc's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Amarin Corporation plc
- Ticker: AMRN
- Exchange: NasdaqGM
- Founded: 1989
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$2.360b
- Shares outstanding: 390.13m
- Website: https://www.amarincorp.com
Number of Employees
Location
- Amarin Corporation plc
- Grand Canal Docklands
- Block C
- Dublin
- Co. Dublin
- 2
- Ireland
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| AMRN | NasdaqGM (Nasdaq Global Market) | Yes | ADR EACH REP 1 ORD GBP0.50 | US | USD | Apr 1993 |
| EH3A | DB (Deutsche Boerse AG) | Yes | ADR EACH REP 1 ORD GBP0.50 | DE | EUR | Apr 1993 |
Biography
Amarin Corporation plc, a pharmaceutical company, develops and commercializes therapeutics for the treatment of cardiovascular diseases in the United States. The company’s lead product is Vascepa, a prescription-only omega-3 fatty acid capsule, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It is also involved in developing REDUCE-IT for the treatment of patients with high triglyceride levels who are also on statin therapy for elevated low-density lipoprotein cholesterol levels. The company sells its products principally to wholesalers and specialty pharmacy providers through direct sales force. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, and eicosapentaenoic acid. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/04/10 07:14 |
| End of Day Share Price | 2020/04/09 00:00 |
| Earnings | 2019/12/31 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.